QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Dermira Stock Price, News & Analysis (NASDAQ:DERM)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$5.54
$6.87
50-Day Range
$18.73
$18.85
52-Week Range
$5.25
$19.48
Volume
536,644 shs
Average Volume
185,571 shs
Market Capitalization
$107.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Dermira MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3.1% Upside
$6.00 Price Target
Short Interest
Healthy
0.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Dermira in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$232,140 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.16) to ($0.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

881st out of 954 stocks

Pharmaceutical Preparations Industry

336th out of 362 stocks


DERM stock logo

About Dermira Stock (NASDAQ:DERM)

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.


DERM Stock News Headlines

4 Growth Stocks to Buy Ahead of a Strong Year-End Rally
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Journey Medical Gains 40%, Insider Trades Reap Benefit
Arvinas (NASDAQ: ARVN)
Why Are Journey Medical Shares Trading Higher Today
See More Headlines
Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermira and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DERM
Fax
N/A
Employees
333
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+3.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-29,630,000.00
Pretax Margin
-15.33%

Debt

Sales & Book Value

Annual Sales
$73.67 million
Book Value
$0.96 per share

Miscellaneous

Free Float
14,914,000
Market Cap
$107.73 million
Optionable
Not Optionable
Beta
0.82
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Thomas G. Wiggans (Age 67)
    Co-Founder, CEO & Chairman
  • Dr. Eugene Andrew Bauer (Age 77)
    Co-Founder, Chief Medical Officer & Director
  • Mr. Andrew L. Guggenhime (Age 51)
    Chief Financial Officer
  • Ms. Lori Lyons-Williams (Age 42)
    Chief Commercial Officer
  • Mr. Christopher M. Griffith (Age 43)
    Co-Founder and Chief Bus. & Strategy Officer














DERM Stock Analysis - Frequently Asked Questions

Should I buy or sell Dermira stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DERM shares.
View DERM analyst ratings
or view top-rated stocks.

What is Dermira's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for Dermira's shares. Their DERM share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price.
View analysts price targets for DERM
or view top-rated stocks among Wall Street analysts.

Are investors shorting Dermira?

Dermira saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 44,600 shares, a decrease of 45.2% from the October 31st total of 81,400 shares. Based on an average trading volume of 99,300 shares, the short-interest ratio is currently 0.4 days. Approximately 0.7% of the shares of the stock are sold short.
View Dermira's Short Interest
.

When is Dermira's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our DERM earnings forecast
.

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.96. The biopharmaceutical company earned $34.54 million during the quarter, compared to analyst estimates of $16.88 million. Dermira had a negative net margin of 15.46% and a negative trailing twelve-month return on equity of 118.05%.

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN).

When did Dermira IPO?

(DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

This page (NASDAQ:DERM) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -